Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bellerophon Ther Com (BLPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,882
  • Shares Outstanding, K 57,470
  • Annual Sales, $ 0 K
  • Annual Income, $ -54,820 K
  • 36-Month Beta -0.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 58.69

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.15 +5.58%
on 05/08/18
2.50 -9.20%
on 05/18/18
+0.03 (+1.34%)
since 04/25/18
3-Month
1.60 +41.87%
on 03/01/18
2.50 -9.20%
on 05/18/18
+0.28 (+14.07%)
since 02/23/18
52-Week
1.00 +127.00%
on 09/13/17
2.74 -17.15%
on 12/18/17
+0.89 (+64.49%)
since 05/25/17

Most Recent Stories

More News
Bellerophon to Present Positive Results from Phase 2 Study of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it will present the previously reported top-line results from...

BLPH : 2.27 (+0.44%)
Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter...

BLPH : 2.27 (+0.44%)
Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that, following the receipt of minutes from a recent meeting with...

BLPH : 2.27 (+0.44%)
Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher

Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 12% on the day.

EXAS : 51.82 (-1.95%)
BLPH : 2.27 (+0.44%)
Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%

Alexion (ALXN) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.

BLPH : 2.27 (+0.44%)
ALXN : 117.74 (+0.51%)
Pick 3 Biotech Money-Spinning Bets Amid Market Instability

The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.

OMED : 2.80 (+0.72%)
NVAX : 1.68 (-2.33%)
BLPH : 2.27 (+0.44%)
Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will...

BLPH : 2.27 (+0.44%)
Blog Exposure - Intercept Pharma to Present Multiple New Ocaliva Data at International Liver Congress 2018

Stock Monitor: Bellerophon Therapeutics Post Earnings Reporting

ICPT : 71.07 (+1.88%)
BLPH : 2.27 (+0.44%)
Will Bellerophon Therapeutics (BLPH) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Bellerophon Therapeutics, Inc. (BLPH).

BLPH : 2.27 (+0.44%)
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter...

BLPH : 2.27 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade BLPH with:

Business Summary

Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton,...

See More

Key Turning Points

2nd Resistance Point 2.40
1st Resistance Point 2.33
Last Price 2.27
1st Support Level 2.20
2nd Support Level 2.14

See More

52-Week High 2.74
Last Price 2.27
Fibonacci 61.8% 2.08
Fibonacci 50% 1.87
Fibonacci 38.2% 1.66
52-Week Low 1.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar